Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q2 2020 Arbutus Biopharma Corp Earnings Call Transcript

Aug 07, 2020 / 12:45PM GMT
Release Date Price: $3.8 (-13.04%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporate 2020 Second Quarter Financial Results and Corporate Update Conference Call.

(Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would like to hand the conference over to one of your speakers today, Ms. Pam Murphy. Ma'am, please go ahead.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Good morning, and thank you for joining Arbutus' Q2 2020 Conference Call. On the call from the Arbutus Executive team are Bill Collier, President and Chief Executive Officer; Dr. Mike Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and Dave Hastings, Chief Financial Officer.

Bill will begin with a summary of recent accomplishments and a review of Arbutus' corporate objective, followed by Gaston and Mike Sofia, who will provide you with updates on the clinical development of AB-729, Arbutus' early-stage HBV program -- pipeline and its COVID-19 research efforts

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot